This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TORC vs. WHWK, VIRI, PYRGF, VHAQ, AADI, OSTX, NBRV, ATNM, EGRX, and ELYMShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Whitehawk Therapeutics (WHWK), Virios Therapeutics (VIRI), PyroGenesis Canada (PYRGF), Viveon Health Acquisition (VHAQ), Aadi Bioscience (AADI), OS Therapies (OSTX), Nabriva Therapeutics (NBRV), Actinium Pharmaceuticals (ATNM), Eagle Pharmaceuticals (EGRX), and Eliem Therapeutics (ELYM). resTORbio vs. Its Competitors Whitehawk Therapeutics Virios Therapeutics PyroGenesis Canada Viveon Health Acquisition Aadi Bioscience OS Therapies Nabriva Therapeutics Actinium Pharmaceuticals Eagle Pharmaceuticals Eliem Therapeutics Whitehawk Therapeutics (NASDAQ:WHWK) and resTORbio (NASDAQ:TORC) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Which has more risk & volatility, WHWK or TORC? Whitehawk Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, resTORbio has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Does the media favor WHWK or TORC? In the previous week, Whitehawk Therapeutics' average media sentiment score of 0.00 equaled resTORbio'saverage media sentiment score. Company Overall Sentiment Whitehawk Therapeutics Neutral resTORbio Neutral Do insiders and institutionals believe in WHWK or TORC? 52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 46.2% of resTORbio shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 11.8% of resTORbio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better valuation and earnings, WHWK or TORC? Whitehawk Therapeutics has higher revenue and earnings than resTORbio. resTORbio is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWhitehawk Therapeutics$25.98M3.61-$63.69M$0.1612.44resTORbioN/AN/A-$82.74M-$2.41-0.28 Is WHWK or TORC more profitable? Whitehawk Therapeutics has a net margin of 99.42% compared to resTORbio's net margin of 0.00%. Whitehawk Therapeutics' return on equity of -56.73% beat resTORbio's return on equity.Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics99.42% -56.73% -48.68% resTORbio N/A -78.12%-71.63% SummaryWhitehawk Therapeutics beats resTORbio on 8 of the 9 factors compared between the two stocks. Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.89M$820.66M$5.50B$8.94BDividend YieldN/A4.84%5.25%4.04%P/E Ratio-0.381.0926.9720.11Price / SalesN/A230.52426.02119.76Price / CashN/A23.4436.8257.86Price / Book0.306.137.985.56Net Income-$82.74M-$27.85M$3.16B$248.40M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.68+5.2%N/A-39.3%$24.89MN/A-0.38N/AWHWKWhitehawk TherapeuticsN/A$1.99+0.5%N/AN/A$93.28M$25.98M0.0040VIRIVirios TherapeuticsN/A$4.80-0.6%$5.00+4.2%+1,782.4%$92.44MN/A-17.785PYRGFPyroGenesis Canada0.1034 of 5 stars$0.35-2.5%N/A-43.0%$64.48M$9.14M-5.7690News CoverageVHAQViveon Health AcquisitionN/A$11.00flatN/A+10.0%$62.26MN/A0.002High Trading VolumeAADIAadi Bioscience0.6374 of 5 stars$1.98-0.5%$1.67-15.8%+44.5%$48.90M$25.07M-0.8740OSTXOS Therapies2.7865 of 5 stars$1.62-6.4%$18.00+1,011.1%N/A$45.52MN/A-1.88N/ANBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070ATNMActinium Pharmaceuticals2.9555 of 5 stars$1.43+0.7%$4.00+179.7%N/A$44.61MN/A-1.0330EGRXEagle PharmaceuticalsN/A$3.25+8.3%N/A-45.9%$42.21M$257.55M0.00100ELYMEliem TherapeuticsN/A$1.28+1.6%N/A-81.1%$38.08MN/A-2.429 Related Companies and Tools Related Companies Whitehawk Therapeutics Alternatives Virios Therapeutics Alternatives PyroGenesis Canada Alternatives Viveon Health Acquisition Alternatives Aadi Bioscience Alternatives OS Therapies Alternatives Nabriva Therapeutics Alternatives Actinium Pharmaceuticals Alternatives Eagle Pharmaceuticals Alternatives Eliem Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TORC) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
